These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32964145)

  • 1. A pilot study on the genetic diversity of
    Thumamo Pokam BD; Yeboah-Manu D; Teyim PM; Guemdjom PW; Wabo B; Fankep ABD; Okonu RE; Asuquo AE
    J Clin Tuberc Other Mycobact Dis; 2020 Dec; 21():100182. PubMed ID: 32964145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa.
    Rabna P; Ramos J; Ponce G; Sanca L; Mané M; Armada A; Machado D; Vieira F; Gomes VF; Martins E; Colombatti R; Riccardi F; Perdigão J; Sotero J; Portugal I; Couto I; Atouguia J; Rodrigues A; Viveiros M
    PLoS One; 2015; 10(5):e0127536. PubMed ID: 26017968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology and multidrug resistance of
    Thumamo Pokam BD; Yeboah-Manu D; Amiteye D; Asare P; Guemdjom PW; Yhiler NY; Azumah Morton SN; Ofori-Yirenkyi S; Laryea R; Tagoe R; Asuquo AE
    Heliyon; 2021 Oct; 7(10):e08152. PubMed ID: 34746460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia.
    Tadesse M; Aragaw D; Dimah B; Efa F; Abebe G
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S48-S49. PubMed ID: 28043605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of GeneXpert Mycobacterium tuberculosis/rifampicin for rapid detection of rifampicin resistant Mycobacterium tuberculosis strains of clinically suspected multi-drug resistance tuberculosis cases.
    Guenaoui K; Harir N; Ouardi A; Zeggai S; Sellam F; Bekri F; Cherif Touil S
    Ann Transl Med; 2016 May; 4(9):168. PubMed ID: 27275481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of the REBA MTB-Rifa® assay for rapid detection of rifampicin resistant Mycobacterium tuberculosis.
    Cho E; Shamputa IC; Kwak HK; Lee J; Lee M; Hwang S; Jeon D; Kim CT; Cho S; Via LE; Barry CE; Lee JS
    BMC Infect Dis; 2013 Oct; 13():478. PubMed ID: 24128118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Analysis of
    Pokam BDT; Yeboah-Manu D; Lawson L; Guemdjom PW; Okonu R; Madukaji L; Yhiler NY; Asuquo AE
    J Epidemiol Glob Health; 2019 Dec; 9(4):259-265. PubMed ID: 31854167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic diversity of
    Reta MA; Said HM; Maningi NE; Wubetu GY; Agonafir M; Fourie PB
    New Microbes New Infect; 2024 Jun; 59():101235. PubMed ID: 38590765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study.
    Mboowa G; Namaganda C; Ssengooba W
    BMC Infect Dis; 2014 Sep; 14():481. PubMed ID: 25190040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study.
    Ullah I; Shah AA; Basit A; Ali M; Khan A; Ullah U; Ihtesham M; Mehreen S; Mughal A; Javaid A
    BMC Infect Dis; 2016 Aug; 16():413. PubMed ID: 27519406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
    Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
    Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.
    Abanda NN; Djieugoué JY; Lim E; Pefura-Yone EW; Mbacham WF; Vernet G; Penlap VM; Eyangoh SI; Taylor DW; Leke RGF
    BMC Infect Dis; 2017 May; 17(1):379. PubMed ID: 28569148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of Cepheid ® Xpert MTB/RIF ® and TB-Biochip ® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis.
    Kurbatova EV; Kaminski DA; Erokhin VV; Volchenkov GV; Andreevskaya SN; Chernousova LN; Demikhova OV; Ershova JV; Kaunetis NV; Kuznetsova TA; Larionova EE; Smirnova TG; Somova TR; Vasilieva IA; Vorobieva AV; Zolkina SS; Cegielski JP
    Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):735-43. PubMed ID: 23263819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycobacterium tuberculosis is the causative agent of tuberculosis in the southern ecological zones of Cameroon, as shown by genetic analysis.
    Assam Assam JP; Penlap Beng V; Cho-Ngwa F; Toukam M; Ngoh AA; Kitavi M; Nzuki I; Nyonka JN; Tata E; Tedom JC; Skilton RA; Pelle R; Titanji VP
    BMC Infect Dis; 2013 Sep; 13():431. PubMed ID: 24028382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Diversity of Mycobacterium tuberculosis Isolates from Assam, India: Dominance of Beijing Family and Discovery of Two New Clades Related to CAS1_Delhi and EAI Family Based on Spoligotyping and MIRU-VNTR Typing.
    Devi KR; Bhutia R; Bhowmick S; Mukherjee K; Mahanta J; Narain K
    PLoS One; 2015; 10(12):e0145860. PubMed ID: 26701129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterium tuberculosis complex drug resistance pattern and identification of species causing tuberculosis in the West and Centre regions of Cameroon.
    Assam-Assam JP; Penlap VB; Cho-Ngwa F; Tedom JC; Ane-Anyangwe I; Titanji VP
    BMC Infect Dis; 2011 Apr; 11():94. PubMed ID: 21496268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia.
    Bates M; Ahmed Y; Chilukutu L; Tembo J; Cheelo B; Sinyangwe S; Kapata N; Maeurer M; O'Grady J; Mwaba P; Zumla A
    Trop Med Int Health; 2013 Sep; 18(9):1134-1140. PubMed ID: 23834035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular epidemiology and drug susceptibility profiles of Mycobacterium tuberculosis complex isolates from Northern Ghana.
    Acquah SKE; Asare P; Osei-Wusu S; Morgan P; Afum T; Asandem DA; Danso EK; Otchere ID; Ofori LA; Obiri-Danso K; Kock R; Asante-Poku A; Yeboah-Manu D
    Int J Infect Dis; 2021 Aug; 109():294-303. PubMed ID: 34273514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampicin resistance among Mycobacterium tuberculosis-infected individuals using GeneXpert MTB/RIF ultra: a hospital-based study.
    Kouemo Motse FD; Nsagha DS; Teyim PM; Adiogo D; Kojom Foko LP; Kedy Koum DC; Ngaba GP; Assob Nguedia JC
    Trop Med Int Health; 2021 Feb; 26(2):159-165. PubMed ID: 32946180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.